4. Erleada

(Johnson & Johnson)

Active ingredient: apalutamide
Disease: non-metastatic prostate cancer
Peak sales estimate: $1.3 billion
Approved: Feb. 14, 2018
Company: Johnson & Johnson

The scoop: In February, J&J’s Erleada picked up the first FDA approval for non-metastatic, castration-resistant prostate cancer, while also being the first to do so using a new clinical trial endpoint of metastasis-free survival. In addition, it was greenlighted months before its decision date—giving it a big head start on market share compared to its main competitor, Pfizer and Astellas’ Xtandi (enzalutamide), which was approved for the same indication in July. Erleada also represents J&J’s follow-up to its Janssen unit’s blockbuster prostate cancer drug, Zytiga (abiraterone acetate), which raised $2.5 billion in sales last year but is now facing pressure from generics. In May 2017, J&J listed 11 pipeline candidates it believed could achieve blockbuster status by 2021, with Erleada being the second on the list to receive approval after the PARP inhibitor Zejula (niraparib). — Conor Hale

4. Erleada

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.